Summary of Key Points Core Viewpoint - The average stock price of A-shares is 14.44 yuan, with 34 stocks priced below 2 yuan, the lowest being *ST Changyao at 0.84 yuan [1]. Group 1: Market Overview - As of January 7, the Shanghai Composite Index closed at 4085.77 points, with a relatively small proportion of high-priced and low-priced stocks in the A-share market [1]. - Among the low-priced stocks, 9 are ST stocks, accounting for 26.47% of those priced below 2 yuan [1]. Group 2: Stock Performance - In the low-priced stock category, 4 stocks increased in price today, with the highest gains being 11.94% for Dongtong Tui, 9.94% for Rongsheng Development, and 2.38% for Jiugang Hongxing [1]. - Conversely, 25 stocks declined, with the largest drops being 5.00% for *ST Aowei, 4.55% for *ST Changyao, and 2.88% for *ST Lifang [1]. Group 3: Low-Priced Stock Rankings - The table lists various low-priced stocks, including their latest closing prices, daily price changes, turnover rates, and industry classifications [1][2]. - Notable stocks include *ST Changyao at 0.84 yuan, *ST Lifang at 1.01 yuan, and *ST Aowei at 1.33 yuan, with respective daily changes of -4.55%, -2.88%, and -5.00% [1][2].

Group 1 - Small-cap stocks exhibit higher volatility and activity compared to large-cap stocks, making them more likely to become market leaders [1] - As of January 6, there are 915 stocks with a circulating market value below 3 billion yuan, and 364 stocks with a circulating market value below 2 billion yuan [1] - A total of 1580 stocks have a total market value below 5 billion yuan, with 529 stocks having a total market value below 3 billion yuan [1] Group 2 - The three stocks with the smallest circulating market values are *ST Changyao at 308 million yuan, *ST Aowei at 431 million yuan, and Kuntai Co. at 634 million yuan [1] - The three stocks with the smallest total market values are *ST Changyao at 308 million yuan, *ST Aowei at 486 million yuan, and *ST Lifang at 667 million yuan [1] - A detailed list of stocks with circulating market values below 2 billion yuan includes various sectors such as pharmaceuticals, defense, automotive, and more, highlighting the diversity within small-cap stocks [1][2]

Group 1 - The stock of *ST Changyao closed at 0.88 yuan on January 6, 2026, down 1.12%, with a turnover rate of 15.68% and a trading volume of 549,400 shares, amounting to a transaction value of 47.54 million yuan [1][2] - On January 6, the net outflow of main funds was 858,100 yuan, while retail investors saw a net inflow of 1,088,700 yuan [2] - The company has issued a risk warning regarding the potential termination of its stock listing due to negative net assets for the fiscal year 2024 and the possibility of receiving a non-standard audit opinion for its financial reports [1][2] Group 2 - The company has faced administrative penalties from the China Securities Regulatory Commission (CSRC) for false disclosures in its annual reports from 2021 to 2023, which may lead to mandatory delisting [1] - The stock price has been below 1 yuan for several consecutive days, and if it remains below this threshold for twenty consecutive trading days, it will trigger a delisting event [1] - A subsidiary of the company has been declared bankrupt, and a manager has been appointed [1]

Core Viewpoint - The company *ST Changyao (300391) is at risk of being delisted due to negative net assets and potential non-standard audit opinions, following a series of financial irregularities and a recent bankruptcy of its subsidiary [1]. Financial Performance - As of January 6, 2026, *ST Changyao's stock closed at 0.88 yuan, down 1.12% from the previous trading day, with a total market capitalization of 308 million yuan [1]. - The stock opened at 0.86 yuan, reached a high of 0.91 yuan, and a low of 0.82 yuan, with a trading volume of 47.54 million yuan and a turnover rate of 15.68% [1]. Risk Factors - The company announced that its net assets for the year 2024 are expected to be negative, and it is projected that it will not complete restructuring by 2025, leading to continued negative net assets by the end of 2025 [1]. - The company has received a notice of administrative penalty from the China Securities Regulatory Commission (CSRC) due to false disclosures in its annual reports from 2021 to 2023, which may lead to mandatory delisting for major violations [1]. - The stock price has been below 1 yuan for several consecutive days, and if it remains below this threshold for twenty consecutive trading days, it will trigger a trading delisting [1]. - A subsidiary of the company has been declared bankrupt, and a manager has been appointed [1].

证券代码：300391 证券简称：*ST长药 公告编号：2026-001 长江医药控股股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、财务类强制退市风险 1、公司股票可能被实施财务类强制退市。长江医药控股股份有限公司（以下 简称"公司"或"长药控股"）股票自2025年4月22日起被实施退市风险警示和其 他风险警示，自2025年12月29日起被叠加实施退市风险警示。鉴于公司未在2025 年12月31日前完成重整，2025年度期末净资产预计为负（具体准确的财务数据以公 司正式披露经审计后的2025年年度报告为准）。如公司2025年度期末经审计净资产 为负值，或者2025年度财务会计报告被出具保留意见、无法表示意见或者否定 意见的审计报告，根据《深圳证券交易所创业板股票上市规则》第10.3.11条的规 定，公司触及财务类强制退市情形，公司股票将被终止上市。敬请广大投资者注 意投资风险。 截至本公告披露日，公司可能触及的终止上市情形如下： | 具体情形 | 是否适用 | | --- | --- | ...

Group 1 - The average stock price of A-shares is 14.43 yuan, with 33 stocks priced below 2 yuan, the lowest being *ST Changyao at 0.88 yuan [1] - Among the low-priced stocks, 9 are ST stocks, accounting for 27.27% of the total [1] - In terms of market performance, 25 of the low-priced stocks increased in price, with Yongtai Energy, Dongtong Tui, and *ST Aowei leading the gains at 5.70%, 5.51%, and 5.26% respectively [1] Group 2 - The lowest priced stock, *ST Changyao, has a closing price of 0.88 yuan and a daily turnover rate of 15.68% [1] - Other notable low-priced stocks include *ST Lifan at 1.04 yuan and Dongtong Tui at 1.34 yuan, with daily price changes of 0.00% and 5.51% respectively [1] - The table lists various low-priced stocks along with their latest closing prices, daily price changes, turnover rates, and industry classifications [2]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

Group 1 - The core viewpoint of the article highlights the impressive performance of A-shares in 2025, with significant gains in hard technology stocks, including two stocks, Upway New Materials and Tianpu Co., which saw over 1000% increase in their annual stock prices [1] - In 2025, 538 stocks achieved an annual increase of over 100%, representing 10.05% of the total stocks, indicating a substantial number of doubling stocks [1] - Tianming Technology, part of the automotive parts supply chain and robotics sector, experienced a remarkable annual increase of 152% in 2025, with its stock price hitting a peak after two consecutive 30%涨停 (limit-up) days [5][6] Group 2 - The article reports that during the last week of 2025, over 36% of stocks saw an increase, with 76 stocks rising over 15%, while 27 stocks fell more than 15% [3] - Tianming Technology led the weekly gains with a 65.78% increase, followed by Boke Co. with a 50.42% rise, and the top ten stocks in this period all had cumulative increases exceeding 33% [3] - The article mentions that external factors, such as potential administrative actions from the Trump administration regarding robotics and market anticipation for Tesla's Optimus project, may have contributed to the positive sentiment in the robotics sector [6] Group 3 - The article discusses the bearish performance of Guandao Tui, which saw a decline of over 61% and is set to be delisted on January 5, 2026, after its stock entered the delisting period on December 11, 2025 [8][9] - Guandao Tui's stock price dropped to 0.86 yuan, reflecting a 21.82% decrease by the end of 2025, with a market capitalization of 0.6 billion yuan [9] Group 4 - Foreign investment institutions, including Goldman Sachs and Morgan Stanley, have expressed positive expectations for the Chinese stock market, predicting a potential 38% increase by the end of 2027 [12] - The focus of foreign investment is on structured opportunities in technology innovation, particularly in artificial intelligence, semiconductors, and high-end manufacturing, as well as green energy transition industries [12] - The article notes that foreign capital is primarily flowing into high-quality Chinese assets, including technology leaders and high-dividend stocks, indicating a preference for value investment [12]

Market Overview - As of December 31, 2025, A-shares concluded trading for the year with mixed performance across major indices. The Shanghai Composite Index closed at 3968.84 points, up 0.13% for the week, while the Shenzhen Component Index fell 0.58% to 13525.02 points, and the ChiNext Index dropped 1.25% to 3203.17 points [2] - Over 36% of individual stocks experienced gains during the week, with 76 stocks rising over 15% and 27 stocks declining more than 15%. Key sectors that saw gains included oil and petrochemicals, defense and military, media, automotive, and machinery equipment, while public utilities, food and beverage, electric equipment, pharmaceutical and biological, and non-bank financial sectors faced declines [2] Top Performing Stocks - Tianming Technology (920270.BJ) led the weekly gainers with a remarkable 65.78% increase, followed by Boke Co., Ltd. (688160.SH) with a 50.42% rise. The top ten stocks in this week's bull list all recorded gains exceeding 33% [4] - Tianming Technology operates in the automotive parts supply chain and robotics sector, focusing on the research, development, production, and sales of winches, electric pedals, and off-road modification equipment. The stock surged after hitting a recent low, achieving two consecutive 30% daily limits on December 30-31, 2025 [5] Underperforming Stocks - Guangdao Tui (920680.BJ) was the worst performer, with a significant drop of 61.26%, leading to its impending delisting on January 5, 2026. Other notable decliners included Dongtong Tui (300379.SZ) and *ST Changyao (300391.SZ), both experiencing declines over 22% [9] - Guangdao Tui specializes in network security products and intelligent network application management platforms. The stock faced a sharp decline after previously being the top gainer with a 74.80% increase the week prior [9][10] - Dongtong Tui's stock was also placed under a delisting notice, with trading expected to end on January 21, 2026, following a 15-day trading period [10][11] Sector Insights - The robotics sector has shown strong performance recently, with significant interest driven by new product launches and potential government initiatives related to robotics. Analysts suggest that the integration of liquid cooling and robotics with automotive parts could create new growth opportunities within the industry [6][7]

Core Insights - The domestic pharmaceutical industry faced unprecedented challenges in 2025 due to policy adjustments, capital withdrawal, and intense competition, leading to a brutal industry reshuffle [2] - The shift in industry dynamics emphasizes clinical value as the core focus, with capital returning to rationality and competition shifting towards hard power [2] Group 1: Company Failures - *ST Changyao faced multiple crises, including a failed restructuring and financial fraud, resulting in a net asset of -643 million yuan and facing dual delisting risks [3] - Simi Biological, an early player in the mRNA field, entered bankruptcy liquidation due to a broken funding chain after raising over 1.3 billion yuan from 2020 to 2023 [5] - Green Valley Pharmaceutical's core product, "Jiuyi Yi," faced production halts due to expired registration and financial difficulties, leading to operational paralysis [6] - *ST Longjin was delisted due to reliance on a single product, with sales dropping significantly after price reductions and failed diversification attempts [7] - Shanghai Jinzhongnuomei, once a rising star, faced bankruptcy liquidation due to funding issues and high R&D costs [8] - Lizhu Group exited the PD-1 market after incurring significant losses, highlighting the challenges of entering saturated markets [9] - Ruike Biological's founder lost control of the company despite nearing commercialization of a core product, reflecting the struggles of innovation-driven firms [10] - Betta Pharmaceuticals faced a trust crisis due to overdue milestone payments, exposing cash flow issues in the innovative drug sector [11] - Keyuan Pharmaceutical's 3.58 billion yuan acquisition plan fell through, missing a critical transformation opportunity amid market changes [13] - Jikai Gene's founder faced legal issues due to an inability to repay 227 million yuan in debt, illustrating the pressures of capital constraints on companies [14]